Heterogenous Model of Temozolomide Resistance in Glioblastoma Reveals Phenotypic Shifts in Drug Response and Migratory Potential

Glioblastoma (GBM) is the most common and aggressive primary malignant brain tumor in adults, with limited survival outcomes due to tumor recurrence, mainly driven by GBM cell invasion and therapy resistance. Although temozolomide (TMZ) remains the standard‐of‐care chemotherapeutic, its long‐term ef...

詳細記述

書誌詳細

主要な著者:	Victoria A. Kriuchkovskaia, Ela K. Eames, Sydney A. McKee, Paul J. Hergenrother, Rebecca B. Riggins, Brendan A. C. Harley
フォーマット:	Artigo
言語:	Inglês
出版事項:	Wiley-VCH 2026-06-01
シリーズ:	Advanced NanoBiomed Research
主題:	chemotherapy resistance glioblastoma (GBM) hydrogel methylguanine methyltransferase (MGMT) temozolomide (TMZ)
オンライン･アクセス:	https://doi.org/10.1002/anbr.202500244
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!